Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
Executive Summary
REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.
Topics
- Subjects
- Financing
- StartUps and SMEs
- Research & Development
- Commercial
- Deals
- Therapy Areas
- Infectious Diseases
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC100478
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC100478
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.